Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Nexalin Technology (Nasdaq:NXL) and Calidi Biotherapeutics will be featured on Bloomberg TV's RedChip Small Stocks, Big Money show on October 26, 2024, at 7 p.m. ET. Nexalin's CEO Mark White will discuss their non-invasive neurostimulation technology for mental health treatment, including the Gen-3 HALO Clarity device, targeting a market projected to reach $537 billion by 2030. The technology addresses conditions like insomnia, PTSD, and traumatic brain injuries. Calidi's Chief Business Officer Stephen Thesing will present their oncolytic virotherapy developments for cancer treatment, featuring both systemic and localized approaches with engineered viruses protected by cell-based technologies.
Nexalin Technology (Nasdaq:NXL) e Calidi Biotherapeutics saranno presentati nel programma RedChip Small Stocks, Big Money di Bloomberg TV il 26 ottobre 2024, alle 19:00 ET. Il CEO di Nexalin, Mark White, discuterà della loro tecnologia di neurostimolazione non invasiva per il trattamento della salute mentale, inclusi il dispositivo Gen-3 HALO Clarity, mirando a un mercato che si prevede raggiungerà i 537 miliardi di dollari entro il 2030. La tecnologia affronta condizioni come insonnia, PTSD e lesioni cerebrali traumatiche. Stephen Thesing, Chief Business Officer di Calidi, presenterà i progressi della loro viroterapia oncolitica per il trattamento del cancro, evidenziando approcci sia sistemici che localizzati con virus ingegnerizzati protetti da tecnologie basate su cellule.
Nexalin Technology (Nasdaq:NXL) y Calidi Biotherapeutics aparecerán en el programa RedChip Small Stocks, Big Money de Bloomberg TV el 26 de octubre de 2024 a las 7 p.m. ET. El CEO de Nexalin, Mark White, hablará sobre su tecnología de neuroestimulación no invasiva para el tratamiento de la salud mental, incluyendo el dispositivo Gen-3 HALO Clarity, apuntando a un mercado que se proyecta alcanzará los 537 mil millones de dólares para 2030. La tecnología aborda condiciones como insomnio, PTSD y lesiones cerebrales traumáticas. Stephen Thesing, Director de Negocios de Calidi, presentará sus desarrollos en viroterapia oncolítica para el tratamiento del cáncer, destacando enfoques tanto sistémicos como localizados con virus diseñados protegidos por tecnologías basadas en células.
Nexalin Technology (Nasdaq:NXL)와 Calidi Biotherapeutics는 2024년 10월 26일 오후 7시(동부 표준시)에 Bloomberg TV의 RedChip Small Stocks, Big Money 쇼에서 소개됩니다. Nexalin의 CEO 마크 화이트는 정신 건강 치료를 위한 비침습적 신경 자극 기술, 특히 Gen-3 HALO Clarity 장치에 대해 논의할 예정이며, 이 시장은 2030년까지 5,370억 달러에 이를 것으로 예상됩니다. 이 기술은 불면증, PTSD 및 외상성 뇌 손상과 같은 질환을 다룹니다. Calidi의 비즈니스 책임자 스티븐 테싱은 암 치료를 위한 종양 용해 바이러스 치료 개발을 소개하며, 세포 기반 기술로 보호된 엔지니어링된 바이러스를 활용한 전신 및 국소적 접근 방식을 강조합니다.
Nexalin Technology (Nasdaq:NXL) et Calidi Biotherapeutics seront présentés dans l'émission RedChip Small Stocks, Big Money de Bloomberg TV le 26 octobre 2024 à 19h00 ET. Mark White, le PDG de Nexalin, discutera de leur technologie de neurostimulation non invasive pour le traitement de la santé mentale, y compris le dispositif Gen-3 HALO Clarity, visant un marché qui devrait atteindre 537 milliards de dollars d'ici 2030. La technologie traite des conditions telles que l'insomnie, le PTSD et les traumatismes crâniens. Stephen Thesing, directeur commercial de Calidi, présentera leurs développements en virothérapie oncolytique pour le traitement du cancer, mettant en avant des approches systémiques et localisées avec des virus conçus et protégés par des technologies basées sur des cellules.
Nexalin Technology (Nasdaq:NXL) und Calidi Biotherapeutics werden am 26. Oktober 2024 um 19 Uhr ET in der Sendung RedChip Small Stocks, Big Money von Bloomberg TV vorgestellt. Der CEO von Nexalin, Mark White, wird über ihre nicht-invasive Neurostimulations-Technologie zur Behandlung von psychischen Erkrankungen sprechen, einschließlich des Gen-3 HALO Clarity Geräts, das auf einen Markt abzielt, der bis 2030 voraussichtlich 537 Milliarden Dollar erreichen wird. Diese Technologie befasst sich mit Erkrankungen wie Schlaflosigkeit, PTSD und traumatischen Hirnverletzungen. Stephen Thesing, Chief Business Officer von Calidi, wird die Entwicklungen ihrer onkolytischen Virotherapie zur Krebsbehandlung vorstellen, wobei sowohl systemische als auch lokale Ansätze mit von Zellen geschützten Desig-Viren hervorgehoben werden.
- Nexalin's technology addresses a large market projected to reach $537 billion by 2030
- Company's Gen-3 HALO Clarity device offers non-invasive alternative to pharmacological treatments
- National TV exposure on Bloomberg TV, reaching estimated 73 million homes
- None.
ORLANDO, FL / ACCESSWIRE / October 25, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and Calidi Biotherapeutics, Inc. (NYSE American:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 26, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Access the interviews in their entirety at:
In an exclusive interview, Mark White, CEO of Nexalin Technology, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update. Nexalin stands at the forefront of the mental health treatment revolution with its cutting-edge, non-invasive neurostimulation technology. By focusing on deep brain stimulation, Nexalin's devices, particularly the advanced Gen-3 HALO™ Clarity, offer an alternative to traditional pharmacological treatments. This technology has shown clinically meaningful improvements in treating conditions such as insomnia, PTSD, and traumatic brain injuries-conditions that affect millions but have limited effective treatments-positioning Nexalin as an emerging leader in a market projected to reach
Stephen Thesing, Chief Business Officer of Calidi, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate update. Calidi is at the forefront of oncolytic virotherapy (OV), a promising multi-billion-dollar area in cancer treatment. Calidi is pioneering the development of both systemic and localized OVs, leveraging engineered viruses to target and destroy cancer cells while arming the immune system for a comprehensive attack on tumors. Calidi's cell-based technologies uniquely protect OVs from immune system elimination, ensuring higher efficacy and opening the tumor microenvironment to treatment. This approach has shown promising efficacy in initial studies, while their breakthrough IV-based technology and direct tumor administration methods differentiate them within the multi-billion-dollar oncology field.
Nexalin and Calidi are clients of RedChip Companies. Please read our full disclosures at https://www.redchip.com/legal/disclosures.
About Nexalin Technology, Inc.
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin's products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman. Additional information about the Company is available at: https://nexalin.com/.
About Calidi Biotherapeutics
Calidi Biotherapeutics (NYSE American:CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi's novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi's clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi's preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com.
About RedChip Companies
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 32 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
To learn more about RedChip's products and services, please visit:
https://www.redchip.com/corporate/investor_relations
"Discovering Tomorrow's Blue Chips Today"™
Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/
Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies
Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/
Follow RedChip on Twitter: https://twitter.com/RedChip
Follow RedChip on YouTube: https://www.youtube.com/@redchip
Follow RedChip on Rumble: https://rumble.com/c/c-3068340
Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest
Contact:
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com
--END--
SOURCE: RedChip
View the original press release on accesswire.com
FAQ
When will Nexalin Technology (NXL) appear on Bloomberg TV's RedChip show?
What market size is Nexalin Technology (NXL) targeting with its neurostimulation technology?
What conditions does Nexalin's (NXL) Gen-3 HALO Clarity device treat?
